MA55604B1 - Dérivés de pyrrolotriazine pour le traitement de maladies liées au kit- and pdgfra - Google Patents

Dérivés de pyrrolotriazine pour le traitement de maladies liées au kit- and pdgfra

Info

Publication number
MA55604B1
MA55604B1 MA55604A MA55604A MA55604B1 MA 55604 B1 MA55604 B1 MA 55604B1 MA 55604 A MA55604 A MA 55604A MA 55604 A MA55604 A MA 55604A MA 55604 B1 MA55604 B1 MA 55604B1
Authority
MA
Morocco
Prior art keywords
pdgfra
treatment
kit
related diseases
pyrrolotriazine derivatives
Prior art date
Application number
MA55604A
Other languages
English (en)
Other versions
MA55604A (fr
Inventor
Joseph L. Kim
Thomas A. DINEEN
Timothy Guzi
Original Assignee
Blueprint Medicines Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corporation filed Critical Blueprint Medicines Corporation
Publication of MA55604A publication Critical patent/MA55604A/fr
Publication of MA55604B1 publication Critical patent/MA55604B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés représentés par la formule I, des sels pharmaceutiques de ceux-ci, et/ou des solvates de l'un quelconque de ceux-ci, qui sont utiles pour le traitement de maladies et d'états liés aux KIT et PDGFRa mutants et qui présentent un profil ayant pour avantage de ne pas pénétrer dans le cerveau pour le traitement de maladies et d'états liés aux KIT et PDGFRa mutants. La présente invention concerne également des procédés de traitement de tumeurs stromales gastro-intestinales et de mastocytose systémique.
MA55604A 2019-04-12 2020-04-08 Dérivés de pyrrolotriazine pour le traitement de maladies liées au kit- and pdgfra MA55604B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962833529P 2019-04-12 2019-04-12
US201962911016P 2019-10-04 2019-10-04
US201962930240P 2019-11-04 2019-11-04
EP20721083.2A EP3953357B1 (fr) 2019-04-12 2020-04-08 Dérivés de pyrrolotriazine pour le traitement de maladies liées au kit- and pdgfra
PCT/US2020/027177 WO2020210293A1 (fr) 2019-04-12 2020-04-08 Dérivés de pyrrolotriazine pour le traitement de maladies médiées par kit et pdgfra

Publications (2)

Publication Number Publication Date
MA55604A MA55604A (fr) 2022-02-16
MA55604B1 true MA55604B1 (fr) 2024-08-30

Family

ID=70416596

Family Applications (1)

Application Number Title Priority Date Filing Date
MA55604A MA55604B1 (fr) 2019-04-12 2020-04-08 Dérivés de pyrrolotriazine pour le traitement de maladies liées au kit- and pdgfra

Country Status (33)

Country Link
US (2) US12552795B2 (fr)
EP (2) EP4424312A3 (fr)
JP (2) JP7600140B2 (fr)
KR (1) KR102875260B1 (fr)
CN (1) CN113939515B (fr)
AU (1) AU2020272743B2 (fr)
BR (1) BR112021020441A2 (fr)
CA (1) CA3136802A1 (fr)
CL (1) CL2021002656A1 (fr)
CO (1) CO2021015113A2 (fr)
DK (1) DK3953357T3 (fr)
EC (1) ECSP21080096A (fr)
ES (1) ES2980811T3 (fr)
FI (1) FI3953357T3 (fr)
HR (1) HRP20240702T1 (fr)
HU (1) HUE067299T2 (fr)
IL (1) IL287168B2 (fr)
LT (1) LT3953357T (fr)
MA (1) MA55604B1 (fr)
MD (1) MD3953357T2 (fr)
MX (1) MX2021012469A (fr)
MY (1) MY209048A (fr)
PE (1) PE20212331A1 (fr)
PH (1) PH12021552568A1 (fr)
PL (1) PL3953357T3 (fr)
PT (1) PT3953357T (fr)
RS (1) RS65644B1 (fr)
SG (1) SG11202111244XA (fr)
SI (1) SI3953357T1 (fr)
SM (1) SMT202400229T1 (fr)
TW (1) TWI857043B (fr)
WO (1) WO2020210293A1 (fr)
ZA (1) ZA202108104B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7710223B2 (ja) * 2018-04-16 2025-07-18 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
SI3953357T1 (sl) * 2019-04-12 2024-08-30 Blueprint Medicines Corporation Pirolotriazinski derivati za zdravljenje bolezni, posredovanih s KIT in PDGFRA
WO2022081626A1 (fr) * 2020-10-14 2022-04-21 Blueprint Medicines Corporation Compositions et méthodes de traitement de maladies médiées par kit et pdgfra
WO2022081627A1 (fr) * 2020-10-14 2022-04-21 Blueprint Medicines Corporation Compositions et méthodes de traitement de maladies à médiation par kit et pdgfra
HU231413B1 (hu) 2021-02-26 2023-08-28 Egis Gyógyszergyár Zrt. Eljárás avapritinib és intermedierek előállítására
BR112023017780A2 (pt) 2021-03-03 2023-11-21 Blueprint Medicines Corp Métodos sintéticos e intermediários para produção de compostos para tratamento de doenças mediadas por kit e pdgfra
KR20240013720A (ko) * 2021-03-10 2024-01-30 블루프린트 메디신즈 코포레이션 키나아제 저해제의 염 및 고체 형태
CN117794935A (zh) * 2021-03-10 2024-03-29 缆图药品公司 激酶抑制剂的盐和固体形式
CN113278023B (zh) * 2021-07-22 2021-10-15 上海睿跃生物科技有限公司 含氮杂环化合物及其制备方法和应用
WO2023081923A1 (fr) * 2021-11-08 2023-05-11 Frequency Therapeutics, Inc. Inhibiteurs du récepteur du facteur de croissance dérivé des plaquettes (pdgfr) alpha et leurs utilisations
WO2024171143A1 (fr) * 2023-02-17 2024-08-22 Assia Chemical Industries Ltd. Sels et formes solides d'elenestinib

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61238784A (ja) 1985-04-17 1986-10-24 Sumitomo Seiyaku Kk コハク酸イミド誘導体及びその酸付加塩
ES2258459T3 (es) 1999-05-21 2006-09-01 Bristol-Myers Squibb Company Pirrolotriazinas inhibidoras de quinasas.
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
ATE396978T1 (de) 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
BR0309669A (pt) 2002-04-23 2005-03-01 Bristol Myers Squibb Co Compostos de anilina de pirrolo-triazina úteis como inibidores de cinase
TW200508224A (en) 2003-02-12 2005-03-01 Bristol Myers Squibb Co Cyclic derivatives as modulators of chemokine receptor activity
KR101312736B1 (ko) 2003-02-27 2013-09-27 팔라우 파르마 에스에이 피라졸로피리딘 유도체
MY145634A (en) 2003-12-29 2012-03-15 Bristol Myers Squibb Co Pyrrolotriazine compounds as kinase inhibitors
JP5213229B2 (ja) 2004-04-23 2013-06-19 エグゼリクシス， インコーポレイテッド キナーゼ調節因子および使用方法
WO2005115397A2 (fr) 2004-04-29 2005-12-08 Pharmix Corporation Compositions et traitements pour moduler une kinase et/ou une hmg-coa reductase
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP5256047B2 (ja) 2006-01-27 2013-08-07 シャンハイ ヘンルイ ファーマシューティカル カンパニー リミテッド ピロロ［３，２−ｃ］ピリジン−４−オン２−インドリノン（ｉｎｄｏｌｉｎｏｎｅ）プロテインキナーゼ阻害剤
WO2008005956A2 (fr) 2006-07-07 2008-01-10 Bristol-Myers Squibb Company Inhibiteurs de pyrrolotriazine kinase
US8415340B2 (en) 2007-07-25 2013-04-09 Bristol-Myers Squibb Company Triazine kinase inhibitors
WO2009117157A1 (fr) 2008-03-20 2009-09-24 Amgen Inc. Modulateurs d’aurora kinase et procédé d’utilisation
WO2010022055A2 (fr) 2008-08-20 2010-02-25 Amgen Inc. Inhibiteurs de canaux sodiques sensibles au potentiel
US20130023497A1 (en) 2009-06-08 2013-01-24 Chunlin Tao Triazine Derivatives and their Therapeutical Applications
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
CA2789711C (fr) 2010-02-17 2014-08-05 Amgen Inc. Derives d'arylcarboxamide en tant qu'inhibiteurs de canal sodique pour le traitement de la douleur
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
CN102040494A (zh) 2010-11-12 2011-05-04 西北师范大学 对氟苯甲醛的制备方法
SG195100A1 (en) 2011-07-01 2013-12-30 Bayer Ip Gmbh Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos
AU2013312477B2 (en) 2012-09-06 2018-05-31 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
KR102212923B1 (ko) 2012-12-21 2021-02-04 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
WO2014160521A1 (fr) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Dérivés de pipérazine et leur utilisation comme modulateurs de kit
PT3409674T (pt) 2013-10-17 2022-07-18 Blueprint Medicines Corp Processo para preparar composições úteis para tratar distúrbios relacionados com kit
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
WO2016022569A1 (fr) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Composés utiles pour traiter des troubles associés à kit
RU2018106483A (ru) 2015-07-24 2019-08-26 Блюпринт Медсинс Корпорейшн Соединения, подходящие для лечения расстройств, связанных с kit и pdgfr
EP3371171B1 (fr) 2015-11-02 2023-10-25 Blueprint Medicines Corporation Inhibiteurs de ret
AR110963A1 (es) 2017-02-07 2019-05-22 Dae Woong Pharma Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende
KR102398659B1 (ko) 2017-03-17 2022-05-16 주식회사 대웅제약 카이네이즈 저해제로서의 피롤로트리아진 유도체
WO2018183712A1 (fr) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Composés de pyrrolo[1,2-b]pyridazine et compositions utiles pour traiter des troubles liés à kit et pdgfr
CN109400610A (zh) 2017-08-18 2019-03-01 浙江海正药业股份有限公司 吡咯并三嗪类衍生物、其制备方法及其在医药上的用途
CN108191874B (zh) 2018-01-16 2019-11-29 成都施贝康生物医药科技有限公司 一种C-Kit抑制剂及其应用
JP7710223B2 (ja) 2018-04-16 2025-07-18 深▲チェン▼市塔吉瑞生物医薬有限公司 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
US20210261512A1 (en) 2018-05-04 2021-08-26 Inflazome Limited Novel compounds
TW202039862A (zh) 2018-11-12 2020-11-01 美商藍印藥品公司 受體酪氨酸激酶(kit)基因突變
CA3123829A1 (fr) 2018-12-20 2020-06-25 Pfizer Inc. Formes polymorphiques de 4-(2-(5-chloro-2-fluorophenyl)-5-isopropylpyridine-4 (1,3-dihydroxypropane-2-yl)nicotinamide
SI3953357T1 (sl) * 2019-04-12 2024-08-30 Blueprint Medicines Corporation Pirolotriazinski derivati za zdravljenje bolezni, posredovanih s KIT in PDGFRA
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
CN110950872A (zh) 2019-12-25 2020-04-03 武汉九州钰民医药科技有限公司 制备靶向抗癌药avapritinib的方法
CN110938077B (zh) 2019-12-25 2021-04-27 武汉九州钰民医药科技有限公司 合成Avapritinib的方法
WO2022081626A1 (fr) 2020-10-14 2022-04-21 Blueprint Medicines Corporation Compositions et méthodes de traitement de maladies médiées par kit et pdgfra

Also Published As

Publication number Publication date
EP4424312A2 (fr) 2024-09-04
JP2025029094A (ja) 2025-03-05
PT3953357T (pt) 2024-07-24
MY209048A (en) 2025-06-18
MA55604A (fr) 2022-02-16
AU2020272743B2 (en) 2025-10-16
TWI857043B (zh) 2024-10-01
ES2980811T3 (es) 2024-10-03
US12552795B2 (en) 2026-02-17
US20220153748A1 (en) 2022-05-19
FI3953357T3 (fi) 2024-07-15
IL287168B1 (en) 2025-06-01
HUE067299T2 (hu) 2024-10-28
EP3953357A1 (fr) 2022-02-16
JP7600140B2 (ja) 2024-12-16
JP2022526850A (ja) 2022-05-26
MX2021012469A (es) 2022-01-18
KR102875260B1 (ko) 2025-10-23
HRP20240702T1 (hr) 2024-08-16
CN113939515A (zh) 2022-01-14
BR112021020441A2 (pt) 2021-12-14
PE20212331A1 (es) 2021-12-14
CO2021015113A2 (es) 2022-02-28
EP4424312A3 (fr) 2025-01-08
WO2020210293A1 (fr) 2020-10-15
SMT202400229T1 (it) 2024-07-09
ZA202108104B (en) 2024-02-28
CA3136802A1 (fr) 2020-10-15
EP3953357B1 (fr) 2024-04-17
PL3953357T3 (pl) 2024-09-02
AU2020272743A1 (en) 2021-11-11
IL287168A (en) 2021-12-01
CN113939515B (zh) 2024-06-18
SI3953357T1 (sl) 2024-08-30
ECSP21080096A (es) 2022-02-25
CL2021002656A1 (es) 2022-08-26
TW202104231A (zh) 2021-02-01
DK3953357T3 (en) 2024-06-10
KR20220025704A (ko) 2022-03-03
IL287168B2 (en) 2025-10-01
US20200325141A1 (en) 2020-10-15
PH12021552568A1 (en) 2022-07-04
RS65644B1 (sr) 2024-07-31
SG11202111244XA (en) 2021-11-29
LT3953357T (lt) 2024-07-25
US10829493B2 (en) 2020-11-10
MD3953357T2 (ro) 2024-09-30

Similar Documents

Publication Publication Date Title
MA55604B1 (fr) Dérivés de pyrrolotriazine pour le traitement de maladies liées au kit- and pdgfra
JP2007534657A5 (fr)
ZA202101449B (en) 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
ZA202101960B (en) Protein tyrosine phosphatase inhibitors
PH12021552227A1 (en) Protein tyrosine phosphatase inhibitors
EP4548918A3 (fr) Composés tricycliques utilisés en tant qu'inhibiteurs de kras
MXPA04004370A (es) Derivados policiclicos de guanina inhibidores de fosfodiesterasa v.
DK1608350T3 (da) Fremgangsm der til forebyggelse, behandling og diagnosticering af lidelser af proteinaggregation
WO2022109396A8 (fr) Composés et leurs utilisations
MA45598B1 (fr) Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
MX2022011697A (es) Inhibidores de ciclofilina y usos de los mismos.
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
BR0210392A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
DE602004026415D1 (de) Indolylmaleimid derivate
WO2024026484A3 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
ATE386742T1 (de) Imidazonaphthyridine
CA2534634A1 (fr) Azolidinecarbonitriles et leur application comme inhibiteurs de dpp-iv
DE602005027677D1 (de) 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung
WO2020165838A9 (fr) Procédés de traitement de la douleur de surface oculaire
EA200501881A1 (ru) ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ ПИРРОЛА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ HMG-CoA
BRPI0518690A2 (pt) tratamento de doenÇa inflamatària do intestino
EA200600316A1 (ru) ПРОИЗВОДНЫЕ 3-НИТРОПИРАЗОЛО[1,5-a]ПИРИМИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИСПОЛЬЗУЕМЫЕ В НЕМ ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), ЛЕКАРСТВЕННОЕ СРЕДСТВО (ВАРИАНТЫ) И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРА ГАМК(ВАРИАНТЫ)
IL149280A0 (en) Methods, kits and compositions for using pyrrole derivatives